2024
Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma
Chen Y, Zhang Z, Pan F, Li P, Yao W, Chen Y, Xiong L, Wang T, Li Y, Huang G. Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma. Journal Of Experimental & Clinical Cancer Research 2024, 43: 210. PMID: 39075504, PMCID: PMC11285179, DOI: 10.1186/s13046-024-03135-3.Peer-Reviewed Original ResearchConceptsAnti-angiogenesis therapyAnti-angiogenesis treatmentVascular normalizationTumor microenvironmentMagnetic-activated cell sortingAnti-angiogenesisTumor tissuesTumor vascular normalizationEfficacy of chemotherapyHuman lung adenocarcinoma cell line A549Expression of CCL28Lung adenocarcinoma cell line A549Adenocarcinoma cell line A549Adenocarcinoma tumor tissuesStabilization of endothelial cellsClinical biopsy samplesRetinoic acidLung adenocarcinoma tumor tissuesCCL28 proteinMurine tumor tissuesCombination therapyTargeted therapyMultiplex immunohistochemistryState of ischemiaPericyte coverage
2009
Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*
Duh M, Dial E, Choueiri T, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*. Current Medical Research And Opinion 2009, 25: 2081-2090. PMID: 19586325, DOI: 10.1185/03007990903084800.Peer-Reviewed Original ResearchConceptsPer-patient per-monthRenal cell carcinomaAngiogenesis inhibitorsAI therapyCell carcinomaUS commercial health insurance claims databaseAdvanced renal cell carcinomaIV therapyAI groupTreatment of renal cell carcinomaProgression-free survivalTreated with sunitinibBaseline clinical characteristicsAnti-angiogenesis therapyRetrospective claims databaseHealth insurance claims databaseInsurance Claims DatabaseIncremental total costBevacizumab patientsBevacizumab groupOral therapyCost of treatmentBevacizumabClinical characteristicsOff-label
2002
Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin
Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA. Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin. Cancer Biotherapy & Radiopharmaceuticals 2002, 17: 233-246. PMID: 12030117, DOI: 10.1089/108497802753773856.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCollagenCysteineEndostatinsEndothelial Growth FactorsFemaleFibroblast Growth Factor 2In Situ Nick-End LabelingIntercellular Signaling Peptides and ProteinsInterleukin-8LymphokinesMammary Neoplasms, ExperimentalNeovascularization, PathologicPaclitaxelPeptide FragmentsRadionuclide ImagingRatsRats, Inbred F344TechnetiumTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsTumor-bearing ratsAnti-angiogenesis therapyTreatment responseTumor uptakeTUNEL assayAnti-angiogenic treatment responseTumor vascular densityIL-8 expressionTumor-bearing animal modelsCount density ratiosCell viabilityPrognostic indicatorMicrovessel densityVascular densityAnimal modelsEndostatin therapyAntiangiogenic effectsMetastatic potentialTherapyUptake doseCellular uptake assaysEndostatinTissue distributionRatsEthylenedicysteine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply